Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment

Treatment with alemtuzumab induces neutropenia, which is mild in the large majority of pwMS treated. Leucocyte levels following alemtuzumab should be monitored as a marker of efficacy and safety; persistent neutropenia may require treatment.